Welcome to the Library, where you'll find a selection of industry resources including eBooks, Whitepapers, Webinars, Survey Reports, Research Reports and more.
If you are interested in submitting items to the Library, please contact our advertising team
The Library is currently filtered to only show Videos. You can remove this filter by returning to the Library.
Blazing a short path to an accelerated approval in oncology
Cancer drug R&D has attracted billions of dollars in new investments as biopharma companies rush to stake out leading positions in hot new fields of research. At the 2015 BIO conference in Philadelphia, FierceBiotech Editor-in-Chief John Carroll moderates a discussion on the future of cancer R&D, featuring leaders from AstraZeneca, Juno Therapeutics, Merck, Johnson & Johnson and GlaxoSmithKline.
Is this a biotech bubble?
FierceBiotech Editor-in-Chief John Carroll sits down with Bloomberg Intelligence analyst Asthika Goonewardene to discuss the results of an informal survey in which readers weighed in on whether the unprecedented bull market for biotech is sustainable or has transformed into a fragile bubble ready to pop.
Is there more room to boom in biotech in 2015?
FierceBiotech Senior Editor Stacy Lawrence moderates an executive breakfast panel Is there more room to book in biotech in 2015? at the J.P. Morgan Healthcare Conference in San Francisco, CA. Lawrence's panel features Ken Drazan, the head of Johnson & Johnson Innovation in California; Dennis Aisling, founder of Aisling Capital; Rajeev Shah, portfolio manager at RA Capital; Rahul Chaudhary, managing director and head of capital markets at Leerink; and Kurt von Emster, partner at Abingworth.
Fast Phase IIIs
FierceBiotech Editor-in-Chief John Carroll moderates an executive breakfast panel, Fast Phase IIIs at the BIO International Convention in Boston, MA. Carroll's panel features bluebird bio CEO Nick Leschly, Pfizer Senior Vice President Jose-Carlos Gutierrez-Ramos, Agios CEO David Schenkein, GlaxoSmithKline Vice President Jason Gardner and Sanofi Head of Boston R&D Jim Burns.